APLS - Apellis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.82
+0.06 (+0.30%)
At close: 4:00PM EDT

19.82 0.00 (0.00%)
After hours: 5:22PM EDT

Stock chart is not supported by your current browser
Previous Close19.76
Open19.84
Bid17.31 x 800
Ask19.90 x 800
Day's Range19.28 - 20.00
52 Week Range11.45 - 32.00
Volume162,767
Avg. Volume414,150
Market Cap1.252B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.80
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on March 7, 2019, the Compensation Committee of the Board of Directors approved the grant of equity awards to two new employees, as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to the employee's acceptance of employment with the Company. The employees received, in the aggregate, options to purchase 101,078 shares of Apellis common stock.

  • GlobeNewswire8 days ago

    Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $17.00 per share, which includes 900,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less underwriting discounts and commissions. This offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov.

  • GlobeNewswire13 days ago

    Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $17.00 per share, for total gross proceeds of $102 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. In addition, Apellis has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The shares are being offered by Apellis pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”) on December 28, 2018 and amended on February 26, 2019.

  • GlobeNewswire13 days ago

    Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. The shares are being offered by Apellis pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”) on December 28, 2018 and amended on February 26, 2019.

  • Apellis resumes trial after safety investigation
    American City Business Journals14 days ago

    Apellis resumes trial after safety investigation

    The clinical-stage biopharmaceutical company paused the Phase 3 clinical trial of its leading treatment candidate.

  • GlobeNewswire15 days ago

    Apellis Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference

    WALTHAM Mass. and CRESTWOOD, Ky., March 04, 2019 -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel.

  • GlobeNewswire16 days ago

    Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that with the agreement of the independent safety monitoring committee for the Company’s Phase 3 clinical program for APL-2 in patients with Geographic Atrophy (GA), the Company has resumed enrollment in its two Phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2. “Patient safety is our first priority and we feel that we can now reinitiate our Phase 3 program for patients with geographic atrophy with confidence following an in-depth investigation and modifications to the manufacturing process,” said Cedric Francois, CEO and co-founder of Apellis.

  • Apellis lands as much as $250M in financing from drug development company
    American City Business Journals19 days ago

    Apellis lands as much as $250M in financing from drug development company

    Apellis Pharmaceutical's newest deal will support clinical development for rare blood disorders.

  • GlobeNewswire19 days ago

    Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications

    WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development company backed by Blackstone Life Sciences and Abingworth. This collaboration marks the first time that SFJ Pharmaceuticals has partnered with a pre-revenue biopharma company. As part of this collaboration, SFJ and Apellis have entered into an agreement to support the development of APL-2 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • GlobeNewswire21 days ago

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019 Phase 3 Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria Expected to be Fully.

  • GlobeNewswirelast month

    Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s APL-2, a novel inhibitor of complement factor C3, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). APL-2 is currently being studied in a Phase 3 active comparator trial in patients with PNH who remain anemic despite treatment with eculizumab.

  • GlobeNewswirelast month

    Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic anemia (AIHA).

  • GlobeNewswire2 months ago

    Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe

    Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Thomas Lackner as Senior Vice President, Head of Europe. Prior to joining Apellis, Thomas was responsible for developing the global commercial strategy and launch organization for Prothena Biosciences in Europe, for their first global launch in a hematologic rare disease (AL amyloidosis).

  • Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
    Zacks2 months ago

    Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

    Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials.

  • Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the FDA for the treatment of C3 glomerulopathy (C3G). C3 glomerulopathy refers to a group of rare renal disorders in which hyperactivity of the complement system leads to deposition of C3 in the glomeruli, the portion of the kidney responsible for blood filtration. C3G is a disease with a high unmet need, as approximately half of all patients with C3G progress to end-stage renal disease within 10 years of diagnosis, and there is no approved therapy proven to prevent progression.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy

    Apellis Pharmaceuticals Inc. (APLS) today provided an update on the status of its Phase 3 program for APL-2 in patients with Geographic Atrophy (GA). Apellis expects to be able to restart enrollment of its two Phase 3 GA trials (DERBY & OAKS) in Q2 2019 and to have fully enrolled both studies by the end of Q1 2020, within the originally planned timeline for completion. As previously disclosed, the Company voluntarily implemented a temporary pause in dosing in the DERBY and OAKS Phase 3 trials due to observed cases of non-infectious inflammation in patients treated from a single manufacturing lot of APL-2 intravitreal drug product.

  • Benzinga3 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...

  • GlobeNewswire4 months ago

    Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced interim data from its Phase 1b study of APL-2 in treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). Data from the PADDOCK trial were presented in a poster session today at the 60th Annual Meeting of the American Society of Hematology (ASH).

  • GlobeNewswire4 months ago

    Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer

    Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Adam Townsend as Chief Commercial Officer. Prior to joining Apellis, Townsend worked at Biogen in Cambridge, MA., with progressive leadership roles in commercial and corporate development. “We are incredibly pleased to welcome Adam to Apellis’ leadership team.

  • GlobeNewswire4 months ago

    Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Enable Injections inks development deals with pharma firms
    American City Business Journals4 months ago

    Enable Injections inks development deals with pharma firms

    Enable Injections has entered into separate development agreements with two more companies, Apellis Pharmaceuticals and UCB.